Key clinical point: Residual cancer burden (RCB) is strongly associated with long-term survival across breast cancer subtypes.
Major finding: For triple-negative breast cancer, patients with pathologic complete response had a 10-year event-free survival among of 86%, a rate that decreased as RCB increased (RCB-I, 75%; RCB-II, 61%; RCB-III, 25%).
Study details: A meta-analysis of 5,160 patients with breast cancer treated at multiple institutions.
Disclosures: The investigators disclosed relationships with Seattle Genetics, Almac, Syndax, and others.
Yau et al. SABCS 2019..